143 related articles for article (PubMed ID: 16539643)
41. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
[TBL] [Abstract][Full Text] [Related]
42. Acute antibody-mediated rejection in paediatric renal transplant recipients.
Kranz B; Kelsch R; Kuwertz-Bröking E; Bröcker V; Wolters HH; Konrad M
Pediatr Nephrol; 2011 Jul; 26(7):1149-56. PubMed ID: 21461632
[TBL] [Abstract][Full Text] [Related]
43. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
44. ABO-incompatible kidney transplantation.
Schousboe K; Titlestad K; Baudier F; Hansen LU; Bistrup C
Dan Med Bull; 2010 Oct; 57(10):A4197. PubMed ID: 21040684
[TBL] [Abstract][Full Text] [Related]
45. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
46. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
[TBL] [Abstract][Full Text] [Related]
47. The emerging role of rituximab in organ transplantation.
Becker YT; Samaniego-Picota M; Sollinger HW
Transpl Int; 2006 Aug; 19(8):621-8. PubMed ID: 16827678
[TBL] [Abstract][Full Text] [Related]
48. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.
Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C
Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362
[TBL] [Abstract][Full Text] [Related]
49. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Kovac D; Kotnik V; Kandus A
Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
[TBL] [Abstract][Full Text] [Related]
50. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation.
Usuda M; Fujimori K; Koyamada N; Fukumori T; Sekiguchi S; Kawagishi N; Akamatsu Y; Enomoto Y; Satoh K; Satoh A; Ishida K; Moriya T; Satomi S
Transplantation; 2005 Jan; 79(1):12-6. PubMed ID: 15714163
[TBL] [Abstract][Full Text] [Related]
51. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
[TBL] [Abstract][Full Text] [Related]
52. Development of antibody mediated rejection shortly after acute cellular rejection in a pediatric kidney transplantation recipient.
Okada M; Kamei K; Matsuoka K; Ito S
CEN Case Rep; 2018 Nov; 7(2):288-291. PubMed ID: 29949115
[TBL] [Abstract][Full Text] [Related]
53. Expression patterns of B cells in acute kidney transplant rejection.
Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
[TBL] [Abstract][Full Text] [Related]
54. Rituximab in renal transplantation.
Barnett AN; Hadjianastassiou VG; Mamode N
Transpl Int; 2013 Jun; 26(6):563-75. PubMed ID: 23414100
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
56. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
Eisenberg R
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
[TBL] [Abstract][Full Text] [Related]
57. Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient.
Aggarwal A; Pyle J; Hamilton J; Bhat G
Tex Heart Inst J; 2012; 39(6):901-5. PubMed ID: 23304051
[TBL] [Abstract][Full Text] [Related]
58. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
59. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
[TBL] [Abstract][Full Text] [Related]
60. Treatment of humoral rejection with rituximab.
Garrett HE; Groshart K; Duvall-Seaman D; Combs D; Suggs R
Ann Thorac Surg; 2002 Oct; 74(4):1240-2. PubMed ID: 12400781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
